About
- - Company
    - About Sensus Healthcare
    - Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions.
      
      Read More
  - Patient Advocates
  - FAQ
    - - What is SRT?
        We offer a painless, safe and highly effective non-surgical skin cancer treatment that is an alternative to surgery—Superficial Radiation Therapy using the SRT-100™.
        
        Go to FAQ
      - What does SRT treat?
        The SRT-100™ is an excellent treatment option for patients with the following conditions: Keloid scars, Basal cell carcinoma, Squamous cell carcinoma, Metatypical carcinoma, Cutaneous appendage carcinoma, Actinic keratosis, Kaposi’s sarcoma.
        
        Go to FAQ
      - Is SRT right for me?
        The SRT-100™ doesn’t harm surrounding or underlying healthy tissue while targeting cancer cells. The SRT-100™ provides excellent cosmetic outcomes and is a great alternative for patients with various co-morbidities.
        
        Go to FAQ
      - What should I expect?
        You should expect the same results as surgery, but with these additional benefits: No pain, No anesthesia, No cutting, No bleeding, No stitching, No scarring, No interruption of lifestyle, No reconstructive surgery
        
        Go to FAQ
      - Is the SRT-100 safe?
        The SRT-100™ is a safe and proven technology that effectively treats non-melanoma skin cancers, keloid scarring, actinic keratosis and Kaposi’s sarcoma. It is utilized by dermatologists and radiation oncologists all over the world because it delivers good patient outcomes.
        
        Go to FAQ
  - Careers
    - - Sensus - Field Service Engineer
    - View Career Opportunities
Physicians
Patients
Investors
- Corporate Governance Guidelines
- Code of Ethics and Business Conduct
Resources
Contact Us

Report on Skin Acne reduction treatment through Dermoelectroporation®

Dr. Gabriela Vasilescu, M.D.

Vascular Surgery Specialist, PRIM Dept - Montedomini Clinic, via de Malcontenti, 6 – 50100, Florence, Italy

Preliminary Study

To evaluate the safety, tolerability and effectiveness of transdermal delivery of Specific substances for skin acne treatment through Dermoelectroporation®.

Study Design

5 sessions in total.
1 sitting every two/three weeks.
Specific substances delivered
Ultrapeel® Transderm® Meso System
Severe skin acne treated

Materials and Methods

Materials

Substances: Vitamin C (Omeopatia Italiana), Placentex®, (Omeopatia Italiana) Antioxidants(Amway Italia), Lymdiaral (Pascoe Italiana)
•Ultrapeel® Transderm Meso® system from Mattioli Engineering
•Eufoton 808 NM Diode Laser
•Deka Mela Italy KTP 500nm Laser
•Eulite Intense Pulse Light

Methods

Session 1, 2 and 3:
1. Microdermabrasion with sterile crystals,
2. Purifying / Regenerative Mandelic chemical peeling (30%)
3. 9W Defocalized 3 J /CMQ Diode laser application
4. Sterilization of bacterial sites thru
5. 500 nm KTP laser to be alternated with ICG Laserpeel
7W 5J Defocalized at 2,3j every 9 Sqcm.
6. IPL Application with Eulite IPL.

Home follow up on Session 1 to 3:
1. Artistry Skin Balancing programme (Amway Italia)
2. Antioxidants (Amway Italia)
3. Booster clarifying treatment (Q-Med AB (publ))
4. Candida intestinal treatment

Session 4 and 5:
1. Microdermabrasion with sterile crystals,
2. 9W Defocalized 3 J /CMQ Diode laser application
3. Sterilization of bacterial sites thru
4. 500 nm KTP laser
5. Ultrapeel® Transderm Meso® system for Vitamin C, Placentex® and Lymdiaral transdermal delivery

Home follow up on Session 4 and 5:
1. Artistry Skin Balancing programme (Amway Italia)
2. Antioxidants(Amway Italia)
3. Booster clarifying treatment(Q-Med AB (publ)
4. Candida intestinal treatment

Results & Conclusions

1 patient was treated with the following results: 1 patient cleared in 1 session.
The subject was very happy about results
Transdermal delivery is possible and safe with no contraindications

Start your journey to a happy & healthy recovery.